AKUMS DRUGS & PHARMACEUTICALS
|
AKUMS DRUGS & PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | -0.28 | 6.63 | -35.30 | 943.16 | 367.37 |
CEPS(Rs) | 8.84 | 14.72 | -10.92 | 13.48 | 7.71 |
DPS(Rs) | - | - | - | - | - |
Book NAV/Share(Rs) | 49.59 | 50.13 | 86.95 | 6,801.28 | 5,554.34 |
Tax Rate(%) | 101.74 | 34.92 | -29.85 | 28.40 | 61.65 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 2.94 | 8.04 | -2.50 | 10.69 | 7.21 |
EBIT Margin(%) | 0.13 | 5.38 | -4.81 | 6.56 | 5.54 |
Pre Tax Margin(%) | -1.08 | 4.11 | -5.26 | 6.31 | 4.71 |
PAT Margin (%) | 0.02 | 2.68 | -6.83 | 4.52 | 1.81 |
Cash Profit Margin (%) | 3.03 | 5.76 | -4.25 | 7.09 | 4.57 |
Performance Ratios | |||||
ROA(%) | 0.02 | 3.11 | -9.64 | 5.88 | 2.44 |
ROE(%) | 0.11 | 14.61 | -33.30 | 15.32 | 5.53 |
ROCE(%) | 0.43 | 17.59 | -18.00 | 19.01 | 13.23 |
Asset Turnover(x) | 1.26 | 1.16 | 1.41 | 1.30 | 1.35 |
Sales/Fixed Asset(x) | 2.29 | 2.24 | 2.56 | 2.35 | 2.50 |
Working Capital/Sales(x) | 5.72 | 5.96 | 6.21 | 4.71 | 4.64 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.44 | 0.45 | 0.39 | 0.43 | 0.40 |
Receivable days | 73.33 | 86.36 | 70.36 | 74.60 | 79.73 |
Inventory Days | 59.41 | 72.52 | 57.27 | 55.51 | 50.37 |
Payable days | 78.67 | 92.84 | 72.46 | 82.54 | 78.42 |
Valuation Parameters | |||||
PER(x) | - | - | - | - | - |
PCE(x) | - | - | - | - | - |
Price/Book(x) | - | - | - | - | - |
Yield(%) | - | - | - | - | - |
EV/Net Sales(x) | 0.06 | 0.11 | 0.07 | 0.01 | 0.01 |
EV/Core EBITDA(x) | 1.55 | 1.08 | -3.90 | 0.10 | 0.14 |
EV/EBIT(x) | 45.56 | 2.11 | -1.53 | 0.17 | 0.22 |
EV/CE(x) | 0.20 | 0.33 | 0.27 | 0.03 | 0.03 |
M Cap / Sales | - | - | - | - | - |
Growth Ratio | |||||
Net Sales Growth(%) | 14.32 | -0.46 | 34.87 | 12.78 | 20.21 |
Core EBITDA Growth(%) | -59.12 | 655.88 | -122.12 | 54.92 | -1.40 |
EBIT Growth(%) | -97.29 | 211.33 | -198.82 | 33.57 | -9.93 |
PAT Growth(%) | -99.19 | 138.99 | -303.82 | 181.97 | -35.84 |
EPS Growth(%) | -104.25 | 118.78 | -103.74 | 156.73 | -36.56 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | 0.69 | 0.75 | 0.58 | 0.11 | 0.24 |
Current Ratio(x) | 1.60 | 1.48 | 1.46 | 2.00 | 1.71 |
Quick Ratio(x) | 1.08 | 0.91 | 0.90 | 1.26 | 1.17 |
Interest Cover(x) | 0.11 | 4.25 | -10.60 | 26.49 | 6.71 |
Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of AKUMS DRUGS & PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
AKUMS DRUGS & PHARMACEUTICALS | ₹7,474.9 Cr | 4% | 4.4% | NA | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹411,306.0 Cr | -2.5% | 7.6% | 4.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹150,343.0 Cr | -3% | 3.4% | 61.5% | Stock Analytics | |
CIPLA | ₹117,323.0 Cr | -1.6% | 3% | -3.4% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹108,619.0 Cr | -0.3% | 9% | 22.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹95,941.5 Cr | -1.2% | 2.9% | -6.4% | Stock Analytics |
AKUMS DRUGS & PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
AKUMS DRUGS & PHARMACEUTICALS | 4% |
4.4% |
|
SENSEX | -1.8% |
2.7% |
5% |
You may also like the below Video Courses